Key result
Symptomatic pediatric restrictive cardiomyopathy is linked to just ~17% 2-year transplant-free survival.
Why the study?
As evolving screening practices lead to early diagnosis of pediatric restrictive cardiomyopathy, identifying the appropriate timing for transplant listing has become increasingly important.
Does symptomatic presentation predict worse outcomes in children with restrictive cardiomyopathy?
Cohort (n=25)
No
Does symptomatic presentation predict worse outcomes in children with restrictive cardiomyopathy?
Effect estimate: HR 5.17 (95% CI 1.28-20.85)
Absolute Event Rate: 17% vs 57%
p-value: p=0.02
In pediatric restrictive cardiomyopathy, symptomatic presentation is a strong negative prognostic marker associated with significantly worse transplant-free and cardiac event-free survival.
Symptomatic presentation may identify higher-risk pediatric restrictive cardiomyopathy; supports risk stratification but leaves open prospective validation.
Introduction Children with restrictive cardiomyopathy (RCM) traditionally have a poor prognosis, with most patients either dying or requiring heart transplantation within 2 years of diagnosis. The development of symptoms in RCM suggests advanced disease. However, as screening practices evolve and lead to diagnosis of early disease, identifying appropriate timing of transplant listing becomes increasingly important. In this context we compared outcomes of children with RCM presenting with clinical symptoms to those asymptomatic at initial presentation. Methods This retrospective cohort study included 25 patients with RCM presenting to a quaternary care center between 2001 and 2018. Times to transplantation, death, and a composite outcome of adverse cardiac events (CPR, cardioversion, inotropic support, mechanical ventilation, mechanical support, or heart transplant) were compared between those symptomatic and asymptomatic at presentation. Results At 2 years following diagnosis, patients asymptomatic at presentation had a significantly better transplant-free survival at 57% compared to 17% for symptomatic patients ( p = 0.03). Those asymptomatic at diagnosis also had significantly improved cardiac event-free survival at 71% compared to symptomatic patients at 25% ( p = 0.01). In multivariable analysis, cardiac symptoms at presentation remained an independent risk factor for heart-transplant or death [hazard ratio 5.17 (1.28–20.85), p = 0.02]. Conclusion Patients with RCM who are symptomatic at time of diagnosis have significantly worse transplant-free survival and cardiac event-free survival. Given current practice variability in timing of transplant listing, the presence of any cardiac symptoms is an important negative prognostic marker and should prompt urgent transplant listing.
No takes yet. Share an insight, caveat, or question.
Lorenzo et al. (2023) conducted a cohort in Pediatric restrictive cardiomyopathy (n=25). Symptomatic presentation vs. Asymptomatic presentation was evaluated on Transplant-free survival at 2 years (HR 5.17, 95% CI 1.28-20.85, p=0.02). Symptomatic presentation in pediatric restrictive cardiomyopathy significantly reduced 2-year transplant-free survival to 17% compared to 57% in asymptomatic patients (HR 5.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: